News and Stories

Assess your potential eligibility for Roche Alzheimer’s disease clinical studies

07/15/2026

The TRAVELLER study is designed to...

• See if you might be a good fit for a Roche Alzheimer’s disease clinical study where investigational treatments are being tested
• Help find ways that may be used to detect Alzheimer’s disease at an earlier stage

Please note that participating in this study won’t involve receiving any treatment, and it won’t affect any treatments you are currently taking.

Can I participate in this study?
You may be able to participate in the TRAVELLER study if you:

• Are between 50 and 90 years of age
• Have had concerns about your memory or been diagnosed with mild cognitive impairment or mild dementia due to Alzheimer’s disease within the last year

If after participating in the TRAVELLER study you are invited to a Roche Alzheimer’s disease study, it does not mean you have Alzheimer’s disease or that you will be eligible for other Roche studies. Your doctor will review the results from the study and provide you with options.

Why the TRAVELLER study is important for Alzheimer’s disease research?
The TRAVELLER study seeks to identify people who are best suited to participate in one of Roche’s Alzheimer’s disease clinical studies. This study also aims to engage with diverse communities to ensure we include all people living with Alzheimer’s disease, regardless of race, ethnicity, physical or mental ability, religion, and education or income level.

What does it mean to take part in the TRAVELLER study?
If you are interested in joining TRAVELLER, these are the next steps:

Step 1: Discuss your participation with the study team and review and sign a consent form
The study team will talk you through all the details of your potential participation to ensure you understand what it means to take part. If you are happy to participate, you will then sign a consent form to move forward with the study. The study team will then ask you a few questions about yourself and your medical history to check if you are eligible to take part.

STEP 2: Participating in the study
Once you have signed the consent form, the study team will ask you some more questions about yourself and your health. You will also take a short memory test and provide the study team with a blood sample. Your blood sample will be used to understand your overall health and to look at the levels of a protein related to Alzheimer’s disease called pTau217.

Your time commitment to the TRAVELLER study should only take a couple of hours over 1 or 2 days. During that time, you will complete both steps mentioned above.

What happens next?

• If your results show that you may be suitable for an ongoing or an upcoming Alzheimer’s disease study at Roche, you will be referred to the study team for more information within 2 weeks to 6 months after you completed TRAVELLER.
• If your results show that you are not likely to be suitable for any of the ongoing or upcoming Roche studies at this point, your results may be reviewed for studies in the future. You may decide to join TRAVELLER a second time (after at least 6 months) to see if your results change.

Take the next step
If you or someone you know would like to participate in the TRAVELLER study and are interested in learning more, please contact the study team:
Study team contact name: Jasmin Yee
Study centre name: Bruyère Health Research Institute
Study centre address: 43 Bruyère St
Telephone (available from 8:30 to 16:30): 613-562-6262 ext. 1636
Email: jyee@bruyere.org